Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: Correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism

European Journal of Haematology

Volumn 71, Issue 4, 2003, Pages 276-282

  Jensen, Morten Krogh ^a   Riisbro, Rikke ^b   Holten Andersen, Mads N ^b   De Nully Brown, Peter ^a   Junker, Peter ^c   Brünner, Nils ^b   Hasselbalch, Hans C ^a  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Metalloproteinase; Myeloprotiferative disorders; S ICTP; S PIIINP; SuPAR; uPA

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 2 CARBOXYTERMINAL TELOPEPTIDE; GELATINASE A; GELATINASE B; HYALURONIC ACID; PEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; UROKINASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME METABOLISM; FEMALE; HUMAN; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLUBILITY; STATISTICAL SIGNIFICANCE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; BONE MARROW; CASE-CONTROL STUDIES; CHRONIC DISEASE; COLLAGEN; COLLAGEN TYPE I; COLLAGEN TYPE III; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYALURONIC ACID; MIDDLE AGED; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; PEPTIDES; POLYCYTHEMIA VERA; RECEPTORS, CELL SURFACE; THROMBOCYTOSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0141818174     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00134.x     Document Type: Article

References (35)

1. MESA RA, HANSON CA, RAJKUMAR SV, SCHROEDER G, TEFFERI A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-3380.
2. LUNDBERG LG, LERNER R, SUNDELIN P, ROGERS R, FOLKMAN J, PALMBLAD J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-19.
3. LISSE I, HASSELBALCH H, JUNKER P. Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. APMIS 1991;99:171-178.
4. FREY BM, RAFII S, TETERSON M, EATON D, CRYSTAL RG, MOORE MAS. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998;160:691-699.
5. REILLY JT. Pathogenesis of idiopathic myelofibrosis: role of growth factors. J Clin Pathol 1992;45:461-464.
6. MARTYRÉ MC, ROMQUIN N, LE BOUSSE-KERDILES MC, CHEVILLARD S, BENYAHIA B, DUPRIEZ B, DEMORY JL, BANTERS F. Transforming growth factor-ß and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9-16.
7. TEFFERI A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
8. RAMESHWAR P, DENNY TN, STEIN D, GASCÓN P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. J Immunol 1994;153:2819-2830.
9. JENSEN MK, DE NULLY BROWN P, LUND BV, NIELSEN OJ, HASSELBALCH HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000;110:116-124.
10. THIELE J, KVASNICKA HM, FISCHER R, DIEHL V. Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Leuk Lymphoma 1997;24:463-481.
11. LE BOUSSE-KERDILÈS MC, MARTYRÉ MC. Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. Springer Semin Immunopathol 2000;21:491-508.
12. HASSELBALCH H, JUNKER P, HØRSLEV-PETERSEN K, LISSE I, BENTSEN KD. Procollagen type III amino-terminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. Am J Hematol 1990;33:18-26.
13. ANDREASEN PA, EGELUND R, PETERSEN HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
14. DANØ K, RØMER J, NIELSEN BS, BJØRN S, PYKE C, RYGAARD J, LUND LR. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 1999;107:120-127.
15. ANDREASEN PA, KJØLLER L, CHRISTENSEN L, DUFFY MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
16. RIISBRO R, PIIRONEN T, BRÜNNER N, LARSEN B, NIELSEN HJ, STEPHENS RW, HØYER-HANSEN G. Measurements of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay 2002;25:53-56.
17. STEPHENS RW, PEDERSEN AN, NIELSEN HJ, HAMERS MJAG, HØYER-HANSEN G, RØNNE E. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1876-1884.
18. STEPHENS RW, NIELSEN HJ, CHRISTENSEN IJ, THORLACIUSUSSING O, SØRENSEN S, DANØ K, BRÜNNER N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999;91:869-874.
19. JENSEN MK, RIISBRO R, DE NULLY BROWN P, BRÜNNER N, HASSELBALCH HC. Elevated soluble plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. Eur J Haematol 2002;69:43-49.
20. JENSEN MK, HOLTEN-ANDERSEN MN, RIISBRO R, DE NULLY BROWN P, LARSEN MB, HEICKENDORFF L, BRÜNNER N, HASSELBALCH HC. Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. Eur J Haematol 2003; in press.
21. BERK PD, GOLDBERG JD, DONOVAN PB, FRUCHTMAN SM, BERLIN NI, WASSERMAN LR. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol 1986;23:132-143.
22. MURPHY S, ILAND H, ROSENTHAL D, LASZIO J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol 1986;23:177-182.
23. HOLTEN-ANDERSEN MN, MURPHY G, NIELSEN HJ, PEDERSEN AN, CHRISTENSEN IJ, HØYER-HANSEN G, BRÜNNER N, STEPHENS RW. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495-503.
24. GRØNDAHL-HANSEN J, AGERLIN N, MUNKHOLM-LARSEN P, BACH F, NIELSEN LS, DOMBERNOWSKY P, DANØ K. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988;111:42-51.
25. KJELDSEN L, BJERRUM OW, HOVGAARD D, JOHNSEN AH, SEHESTED M, BORREGAARD N. Human neutrophil gelatinase: a marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assay. Eur J Haematol 1992;49:180-191.
26. HEWITT RE, LEACH IH, POWE DG, CLARK IM, CAWSTON TE, TURNER DR. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991;49:666-672.
27. KOSSAKOWSKA AE, EDWARDS DR, LEE SS, URBANSKI LS, STABBLER AL, ZHANG C-L, PHILLIPS BW, ZHANG Y, URBANSKI SJ. Altered balance between matrix metallo-proteinases and their inhibitors in experimental fibrosis. Am J Pathol 1998;153:1895-1902.
28. ARTHUR MJP, MANN DA, IREDALE JP. Tissue inhibitors or metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol 1998;13 (Suppl.):33-38.
29. PYKE C, KRISTENSEN P, RALFKIÆR E, J. G-H, ERIKSEN J, BLASI F, DANØ K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinoma. Am J Pathol 1991;138:1059-1067.
30. NIELSEN BS, SEHESTED M, TIMSHEL S, PYKE C, DANØ K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996;74:168-177.
31. SHETTY S, KUMAR A, JOHNSON AR, PUEBLITZ S, HOLIDAY D, RAGHU G, IDELL S. Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am J Respir Cell Mol Biol 1996;15:78-87.
32. HANNOCKS M-J, OLIVER L, GABRILOVE JL, WILSON EL. Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor-beta. Blood 1992;79:1178-1184.
33. BIGG HF, CAWSTON TE. Effect of retinoic acid in combination with platelet-derived growth factor-BB or transforming growth factor-β on tissue inhibitor of metalloproteinases and collagenase secretion from human skin and synovial fibroblasts. J Cell Physiol 1996;166:84-93.
34. EDWARDS DR, MURPHY G, REYNOLDS JJ, WHITHAM SE, DOCHERTY AJP, ANGEL P, HEATH JK. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899-1904.
35. PLOUGH M, ØSTERGAARD S, GÅRDSVOLL H, KOVALSKI K, HOLST-HANSEN C, HOLM A, OSSOWSKI L, DANØ K. Peptidederived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001;40:12 157-12 168.